<DOC>
	<DOCNO>NCT00006493</DOCNO>
	<brief_summary>The purpose research study effect rosiglitazone , drug usually take Type II diabetes , HIV-associated hyperlipidemia . HIV-associated lipodystrophy medical condition characterize gradual change distribution body fat . The body fat locate extremity face disappear body fat around abdomen upper back increase . Certain biochemical change occur association change fat distribution . Lipid level particularly serum triglyceride increase . HDL , `` good cholesterol '' decrease . Higher normal level insulin insulin resistance also find condition . This latter condition one hallmark Type II diabetes . The protease inhibitor , class HIV medication , associate occurrence HIV-associated lipodystrophy . It suggest biochemical pathway know peripheral peroxisomal activate receptor ( PPAR ) gamma system block leading onset condition . Rosiglitazone new drug approve FDA 1999 treatment type II diabetes . It lower blood sugar improve insulin resistance , mention , hallmark Type II diabetes . It also note improve blood lipid level . Rosiglitazone work stimulate PPAR gamma system . It hop drug turn PPAR system reverse HIV-associated lipodystrophy syndrome .</brief_summary>
	<brief_title>Rosiglitazone Treatment HIV-Associated Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>HIVpositive CD4 count &gt; 500 undetectable viral load Treated protease inhibitor three month Serum triglycerides &gt; 400mg/dl Clinical diagnosis HIVassociated lipodystrophy No history type II diabetes Fasting blood sugar &lt; 126 mg/dl No history liver disease Negative Hepatitis B antigen Hepatitis C antibody Not follow medication : warfarin , digoxin , nifedipine , erythromycin , cyclosporine HMG coAreductase inhibitor Hemoglobin &gt; 11g/dl Women childbearing age must consent barrier contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>HIV-associated hyperlipidemia</keyword>
</DOC>